ANNX Annexon

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference

BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devasting inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 2023 Jefferies London Healthcare Conference on Wednesday, November 15, 2023 at 10:30 a.m. GMT in London.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement pathway activation before it starts. As the only company solely focused on shutting down C1q, Annexon is developing a fit-for-purpose pipeline of therapeutics designed to provide meaningful benefits across multiple diseases of the body, brain and eye. With proof-of concept data in both Guillain-Barré syndrome and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible. To learn more visit annexonbio.com.

Investor Contact:

Chelcie Lister

THRUST Strategic Communications

Media Contact:

Sheryl Seapy

Real Chemistry

949-903-4750



EN
09/11/2023

Underlying

ANNXAnnexon

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Annexon

 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Biosciences to Participate in Upcoming September Investor Conf...

Annexon Biosciences to Participate in Upcoming September Investor Conferences BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 3...

August 27, 2025 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing ...

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq L...

August 18, 2025 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progr...

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Ki...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Selected by EMA to Participate in Product Development Coordina...

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning Vonaprument Selected by EMA as One of ~20 PRIME Development Programs in the Pilot Vonaprument Has the Potential to Be the First Treatment Approved in Europe and the U.S. for Dry AMD with Geographic Atrophy Based on Protection of Visual Acuity and Visual Structures BRI...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ANNX ANNEXON

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER I...

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation Topline Pivotal Phase 3 Data Expected in the Second Half of 2026 Potential for Vonaprument to Be the First Treatment Approved in Europe and the U.S. for Dry ...

July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch